Pharvaris (PHVS) Earnings Date & Reports

Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks... Show more

Get AI intraday signals

A.I. Advisor

published Earnings

PHVS is expected to report earnings to rise 14.05% to -72 cents per share on May 07

Q1'25

Est.

$-0.73

Q4'24

Beat

by $0.08

Q3'24

Missed

by $0.18

Q2'24

Est.

$-0.55

Q1'24

Beat

by $0.04

The last earnings report on April 07 showed earnings per share of -63 cents, beating the estimate of -72 cents. With 39.01K shares outstanding, the current market capitalization sits at 822.30M.

View a ticker or compare two or three

Compare

PHVS